Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-04-30T15:32:35.257Z Has data issue: false hasContentIssue false

Chap. 14 - HUMAN AND BOVINE COLLAGEN-BASED FILLERS

from PART THREE - FILLERS AND NEUROTOXINS

Published online by Cambridge University Press:  06 July 2010

Sorin Eremia
Affiliation:
University of California, Los Angeles, School of Medicine
Get access

Summary

Dermal matrix in adult skin is composed of type I (80 to 85%) and type III collagen (10 to 15%), in addition to glycosaminoglycans and elastin. Decreased collagen synthesis and increased levels of matrix metalloproteinases, including collagenase, result in reduction and alteration in dermal collagen. The art of soft tissue augmentation was directed toward collagen implants in the 1970s at Stanford University, where researchers first studied bovine- and human-derived collagen as injectable implants. In recent years, significant growth has been observed both in the development of newer dermal implants and in patients' interest in treatment with these products.

This chapter will discuss the available animal- and human-derived collagen products, in addition to their clinical applications, advantages, and disadvantages.

BOVINE-DERIVED COLLAGEN IMPLANTS

Bovine-derived collagen implants were introduced in the 1970s for correction of facial lines and were the most popular dermal implants for about two decades in the United States. These products include Zyderm I, Zyderm II, and Zyplast. Zyderm I and Zyderm II contain 35 mg/cc and 65 mg/cc of bovine collagen, respectively, dispersed in a phosphate-based solution and lidocaine. Zyplast is composed of 35 mg/cc of bovine collagen and is cross-linked by 0.0075% gluteraldehyde in addition to lidocaine. Zyderm I and II are intended for correction of superficial, etched-in rhytids and are expected to provide a duration of correction of two to three months. The cross-linked collagen in Zyplast provides more resistance to degradation and extends the duration of correction to four to five months.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alcalay, J, Alkalay, R, Gat, A, Yorav, S. Late-onset granulomatous reaction to Artecoll. Dermatol. Surg. 2003;29:859–62.Google ScholarPubMed
Baumann, L.Soft tissue augmentation. In: Baumann, L, ed., Cosmetic Dermatology Principles and Practice. New York: McGraw-Hill; 2002:155–72.Google Scholar
Baumann, LS, Kerdel, F. The treatment of bovine collagen allergy with cyclosporin. Dermatol. Surg. 1999;25:247–51.CrossRefGoogle ScholarPubMed
Castrow, FF, Krull, EA. Injectable collagen implant – update. J. Am. Acad. Dermatol. 1983;9:889–99.CrossRefGoogle ScholarPubMed
Hanke, CW, Higley, HR, Jolivette, DM, Swanson, NA, Stegman, SJ. Abscess formation and local necrosis after treatment with Zyderm or Zyplast collagen implant. J. Am. Acad. Dermatol. 1991;25:319–26.CrossRefGoogle ScholarPubMed
Hanke, CW, Thomas, JA, Lee, WT, Jolivette, DM, Rosenberg, MJ. Risk assessment of polymyositis/dermatomyositis after treatment with injectable bovine collagen implants. J. Am. Acad. Dermatol. 1996;34:450–4.CrossRefGoogle ScholarPubMed
Kim, KJ, Lee, HW, Lee, MW, Choi, JH, Moon, KC, Koh, JK. Artecoll granuloma: a rare adverse reaction induced by microimplant in the treatment of neck wrinkles. Dermatol. Surg. 2004;30(4 Pt 1):545–7.Google ScholarPubMed
Klein, AW, Elson, ML. The history of substances for soft tissue augmentation. Dermatol. Surg. 2000;26:1096–105.CrossRefGoogle ScholarPubMed
Rosenberg, MJ, Reichlin, M. Is there an association between injectable collagen and polymyositis/dermatomyositis?Arthritis Rheum. 1994;37:747–53.CrossRefGoogle ScholarPubMed
Siegle, RJ, McCoy, JP, Schade, W, et al. Intradermal implantation of bovine collagen: humoral immune responses associated with clinical reactions. Arch. Dermatol. 1984;120:183–9.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×